Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice

Journal of Gene Medicine

Volumn 10, Issue 10, 2008, Pages 1071-1082

  Kucerova, Lucia ^a   Matuskova, Miroslava ^a   Pastorakova, Andrea ^a   Tyciakova, Silvia ^a   Jakubikova, Jana ^a   Bohovic, Roman ^a   Altanerova, Veronika ^a   Altaner, Cestmir ^a  

^a CANCER RESEARCH INSTITUTE   (Slovakia)

Author keywords

5 fluorouracil; Bystander effect; Cellular therapy; Human mesenchymal stem cells; Retrovirus vector

Indexed keywords

CYTOSINE DEAMINASE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUCYTOSINE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MULTIDRUG RESISTANCE PROTEIN 1; OROTATE PHOSPHORIBOSYLTRANSFERASE; PHOSPHORYLASE; RETROVIRUS VECTOR; THYMIDYLATE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; CANCER VACCINE; GLYCOSYLTRANSFERASE; HYBRID PROTEIN; PRODRUG; URACIL PHOSPHORIBOSYLTRANSFERASE;

ADIPOSE TISSUE; ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CARCINOMA; BREAST CARCINOMA; BYSTANDER EFFECT; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER INHIBITION; CELL DIFFERENTIATION; CELL HOMING; COCULTURE; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; ENZYME PRODRUG THERAPY; GENE EXPRESSION; GLIOBLASTOMA; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SCID MOUSE; STEM CELL GENE THERAPY; SUICIDE GENE THERAPY; TUMOR REGRESSION; VIRAL GENE DELIVERY SYSTEM; ADULT; ANIMAL; APOPTOSIS; CANCER TRANSPLANTATION; CYTOLOGY; ENZYMOLOGY; EXPERIMENTAL MELANOMA; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HUMAN; METABOLISM; TUMOR CELL LINE;

MUS; MUS MUSCULUS;

ADIPOSE TISSUE; ADULT; ANIMALS; APOPTOSIS; CANCER VACCINES; CELL LINE, TUMOR; CYTOSINE DEAMINASE; FLUCYTOSINE; GENE THERAPY; GENETIC VECTORS; HUMANS; MELANOMA, EXPERIMENTAL; MESENCHYMAL STEM CELLS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PENTOSYLTRANSFERASES; PRODRUGS; RECOMBINANT FUSION PROTEINS; TRANSDUCTION, GENETIC;

EID: 58149200539     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1239     Document Type: Article

References (44)

1. Vassaux G, Martin-Duque P. Use of suicide genes for cancer gene therapy: study of the different approaches. Expert Opin Biol Ther 2004; 4: 519-530.
2. Wei J, Blum S, Unger M, et al. Embryonic endothelial progenitor cells armed with a suicide gene target hypoxic lung metastases after intravenous delivery. Cancer Cell 2004; 5: 477-488.
3. Aboody KS, Najbauer J, Schmidt NO, et al. Targeting of melanoma brain metastases using engineered neural stem/progenitor cells. Neuro-oncology 2006; 8: 119-126.
4. Kim SK, Kim SU, Park IH, et al. Human neural stem cells target experimental intracranial medulloblastoma and deliver a therapeutic gene leading to tumor regression. Clin Cancer Res 2006; 12: 5550-5556.
5. Danks MK, Yoon KJ, Bush RA, et al. Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma. Cancer Res 2007; 67: 22-25.
6. Aboody KS, Bush RA, Garcia E, et al. Development of a tumor-selective approach to treat metastatic cancer. PLoS ONE 2006; 1: E23.
7. Hamada H, Kobune M, Nakamura K, et al. Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy. Cancer Sci 2005; 96: 149-156.
8. Nakamizo A, Marini F, Amano T, et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005; 65: 3307-3318.
9. Hung SC, Deng WP, Yang WK, et al. Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development monitored by noninvasive in vivo positron emission tomography imaging. Clin Cancer Res 2005; 11: 7749-7756.
10. Stoff-Khalili MA, Rivera AA, Mathis JM, et al. Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res Treat 2007; 105: 157-167.
11. Komarova S, Kawakami Y, Stoff-Khalili MA, Curiel DT, Pereboeva L. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther 2006; 5: 755-766.
12. Reiser J, Zhang XY, Hemenway CS, Mondal D, Pradhan L, La Russa VF. Potential of mesenchymal stem cells in gene therapy approaches for inherited and acquired diseases. Expert Opin Biol Ther 2005; 5: 1571-1584.
13. Fraser JK, Wulur I, Alfonso Z, Hedrick MH. Fat tissue: an underappreciated source of stem cells for biotechnology. Trends Biotechnol 2006; 24: 150-154.
14. Kucerova L, Altanerova V, Matuskova M, Tyciakova S, Altaner C. Adipose tissue derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res 2007; 67: 6304-6313.
15. Keating A. Mesenchymal stromal cells. Curr Opin Hematol 2006; 13: 419-425.
16. Wagner W, Wein F, Seckinger A, et al. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol 2005; 33: 1402-1416.
17. Kern S, Eichler H, Stoeve J, Klüter H, Bieback K. Comparative analysis of mesenchymal stemcells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006; 24: 1294-1301.
18. Schaffler A, Buchler C. Concise review: adipose tissue-derived stromal cells - basic and clinical implications for novel cell-based therapies. Stem Cells 2007; 25: 818-827.
19. Xu Y, Malladi P, Wagner DR, Longaker MT. Adipose-derived mesenchymal cells as a potential cell source for skeletal regeneration. Curr Opin Mol Ther 2005; 7: 300-305.
20. Nakagami H, Maeda K,Morishita R, et al. Adipose tissue-derived stromal cells as a novel option for regenerative cell therapy. J Atheroscler Thromb 2006; 13: 77-81.
21. Kokai LE, Rubin JP, Marra KG. The potential of adipose-derived adult stem cells as a source of neuronal progenitor cells. Plast Reconstr Surg 2005; 116: 1453-1460.
22. Morizono K, De Ugarte DA, Zhu M, et al. Multilineage cells from adipose tissue as gene delivery vehicles. Hum Gene Ther 2003; 14: 59-66.
23. Pereboeva L, Komarova S, Mikheeva G, Krasnykh V, Curiel DT. Approaches to utilize mesenchymal progenitor cells as cellular vehicles. Stem Cells 2003; 21: 389-404.
24. Hlavaty J, Hlubinova K, Altanerova V, Liska J, Altaner C. Treatment of rat gliomas with recombinant retrovirus harboring herpes simplex virus thymidine kinase suicide gene. Neoplasma 1997; 44: 342-347.
25. Hlavaty J, Hlubinova K, Altaner C. Construction and testing of gene therapy retroviral vector expressing bacterial cytosine deaminase gene. Neoplasma 1999; 46: 267-276.
26. Zuk PA, Zhu M, Ashjian P, et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002; 13: 4279-95.
27. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330-338.
28. Okumura K, Shiomi H, Mekata E, et al. Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer. Oncol Rep 2006; 15: 875-882.
29. Jin J, Huang M, Wei HL, Liu GT. Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402). World J Gastroenterol 2002; 8: 1029-1034.
30. Lacueva J, Perez-Ramos M, Soto JL, et al. Multidrug resistance-associated protein (MRP1) gene is strongly expressed in gastric carcinomas. Analysis by immunohistochemistry and real-time quantitative RT-PCR. Histopathology 2005; 46: 389-395.
31. Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct 'side population' of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 2004; 101: 14228-14233.
32. Frank NY, Pendse SS, Lapchak PH, et al. Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding cassette transporter. J Biol Chem 2003; 278: 47156-47165.
33. Kievit E, Nyati MK, Ng E, et al. Yeast cytosine deaminase improves radiosensitization and bystander effect by 5- fluorocytosine of human colorectal cancer xenografts. Cancer Res 2000; 60: 6649-6655.
34. Chung-Faye GA, Chen MJ, Green NK, et al. In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther 2001; 8: 1547-1554.
35. Meyerrose TE, De Ugarte DA, Hofling AA, et al. In vivo distribution of human adipose-derived mesenchymal stem cells in novel xenotransplantation models. Stem Cells 2007; 25: 220-227.
36. Delorme B, Chateauvieux S, Charbord P. The concept of mesenchymal stem cells. Regen Med 2006; 1: 497-509.
37. Muraglia A, Cancedda R, Quarto R. Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model. J Cell Sci 2000; 113: 1161-1166.
38. Baxter MA, Wynn RF, Jowitt SN, Wraith JE, Fairbairn LJ, Bellantuono I. Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. Stem Cells 2004; 22: 675-682.
39. Vacanti V, Kong E, Suzuki G, Sato K, Canty JM, Lee T. Phenotypic changes of adult porcine mesenchymal stem cells induced by prolonged passaging in culture. J Cell Physiol 2005; 205: 194-201.
40. Bonab MM, Alimoghaddam K, Talebian F, Ghaffari SH, Ghavamzadeh A, Nikbin B. Aging of mesenchymal stem cell in vitro. BMC Cell Biol 2006; 7: 14.
41. Conget PA, Allers C, Minguell JJ. Identification of a discrete population of human bone marrow-derived mesenchymal cells exhibiting properties of uncommitted progenitors. J Hematother Stem Cell Res 2001; 10: 749-58.
42. Furukawa T, Yoshimura A, Sumizawa T, et al. Angiogenic factor. Nature 1992; 356: 668.
43. Yasuno M, Mori T, Koike M, et al. Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma. Oncol Rep 2005; 13: 405-412.
44. Kato Y, Matsukawa S, Muraoka R, Tanigawa N. Enhancement of drug sensitivity and a bystander effect in PC-9 cells transfected with a platelet-derived endothelial cell growth factor thymidine phosphorylase cDNA. Br J Cancer 1997; 75: 506-511.